To this end, we showed that approximately 12% of EGFR-mutant NSCLC tumors exhibited high FGFR1 expression, suggesting that EGFR-TKI are driving FGFR1 in patients with primary adenomacarcinoma NSCLC. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.